InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions
InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions
复制标题
DOI：
10.1182/blood-2010-06-289561
复制
发表时间：
2010-11-18
期刊：
影响因子：
20.3
通讯作者：
Weisenburger, Dennis D.
中科院分区：
文献类型：
--
作者：
Turner, Jennifer J.;Morton, Lindsay M.;Weisenburger, Dennis D.
在2008年出版了更新的世界卫生组织（WHO）造血和淋巴组织肿瘤分类后，国际淋巴瘤流行病学联盟（InterLymph）病理学工作组现在提出了基于2001年WHO分类的淋巴肿瘤分级分类的更新，我们于2007年出版了该分类。更新后的分级分类纳入了2008年WHO分类中的所有主要和临时实体，包括基于年龄、部位、某些感染和分子特征的新定义实体，以及边界类别、早期和“原位”病变、临床进展能力有限的疾病、没有现行国际肿瘤疾病分类第3版代码的病变，和免疫缺陷相关的淋巴增生性疾病。WHO亚型定义为分层分组，新定义的组为具有浆细胞分化的小B细胞淋巴瘤和原发性皮肤T细胞淋巴瘤。我们提出了在各种流行病学环境中应用分层分类的方法，包括处理一名患者中共存的多种淋巴瘤亚型以及病理信息不完整的病例的策略。最先进的流行病学研究的病理材料有用的也进行了讨论。我们鼓励流行病学家采用最新的InterLymph分级分类，该分类纳入了最新的世卫组织实体，同时证明了它们与旧分类的关系。（Blood.2010;116（20）：e90-e98）
After publication of the updated World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues in 2008, the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) now presents an update of the hierarchical classification of lymphoid neoplasms for epidemiologic research based on the 2001 WHO classification, which we published in 2007. The updated hierarchical classification incorporates all of the major and provisional entities in the 2008 WHO classification, including newly defined entities based on age, site, certain infections, and molecular characteristics, as well as borderline categories, early and "in situ" lesions, disorders with limited capacity for clinical progression, lesions without current International Classification of Diseases for Oncology, 3rd Edition codes, and immunodeficiency-associated lymphoproliferative disorders. WHO subtypes are defined in hierarchical groupings, with newly defined groups for small B-cell lymphomas with plasmacytic differentiation and for primary cutaneous T-cell lymphomas. We suggest approaches forapplying the hierarchical classification in various epidemiologic settings, including strategies for dealing with multiple coexisting lymphoma subtypes in one patient, and cases with incomplete pathologic information. The pathology materials useful for state-of-the-art epidemiology studies are also discussed. We encourage epidemiologists to adopt the updated InterLymph hierarchical classification, which incorporates the most recent WHO entities while demonstrating their relationship to older classifications. (Blood.2010;116(20):e90-e98)